3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
134
Lung Neoplasms
50
Adenocarcinoma of Lung
18
Adenocarcinoma, Bronchiolo-Alveolar
10
Brain Neoplasms
9
NSCLC
8
Neoplasms
5
Neoplasm Metastasis
5
Adenocarcinoma
4
Respiratory Tract Diseases
3
Carcinoma
3
Thoracic Neoplasms
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Stage IV EGFR Mutated Non-Small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumor, Pleural
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Recurrence
1
Previous Treated Metastatic Non-small Cell Lung Cancer
1
Pleural Effusion, Malignant
1
Parathyroid Neoplasms
1
Non-squamous Non-small Cell Lung Cancer
1
Non-small Cell Lung Cancer Metastatic
1
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Gefitinib
×
Thoracic
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA